SPACInsider Logo
The Latest SPAC News and Rumors: November 15, 2022
by Marlena Haddad on 2022-11-15 at 11:33am

 


Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Elliott discloses new stake in Clarivate, Virusight and Technogenetics expand collaboration, and Apollomics receives FDA Orphan Drug Designation  


Elliott Takes Stake in Clarivate With Take-Private Wave Rising

Elliott Investment Management disclosed a new stake in Clarivate Plc (NYSE:CLVT) amid a wave of take-private transactions in the information services sector.

Clarivate is a provider of critical data, insights and analytics used by universities, corporations, the legal community and other institutions around the world, according to its website. It was purchased from Thomson Reuters Corp. in 2016 by a group of investors led by Onex Corp. and Baring Private Equity Asia.

The company went public in 2019 through a merger with a special purpose acquisition company led by Michael Klein. Several of its top investors are private equity companies, including Leonard Green & Partners, which is its largest shareholder with a 17.3% stake in the company, according to data compiled by Bloomberg.

READ

Virusight and Technogenetics to Expand Collaboration for Global Deployment of Innovative Spectral-Based Pathogens Diagnosis

Virusight Diagnostic (a joint venture subsidiary of Newsight Imaging Ltd.) and Technogenetics today signed a Memorandum of Understanding to expand their collaboration for worldwide commercialization of the 20-second COVID-19 diagnosis solution and to develop additional diagnostic applications utilizing the technology.

On August 30, 2022, Newsight Imaging announced that it has entered into a definitive agreement to become publicly listed through a merger transaction with Vision Sensing Acquisition Corp. (Nasdaq: VSAC), a publicly traded special purpose acquisition company.

READ

Apollomics Inc. Receives FDA Orphan Drug Destination for Vebreltinib for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations 

Apollomics, Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations. The FDA granted the Orphan Drug Designation in August.

As previously announced on Sept. 14, 2022, Apollomics and Maxpro Capital Acquisition Corp. (Nasdaq: JMAC, JMACU, JMACW), announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market.

READ

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia

AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, today announced it has received Human Research Ethics Committee (“HREC”) approval to commence a Phase II clinical trial of its selective translation inhibitor AUM001 in Australia. Ethics approval is confirmation that AUM has completed all the necessary pre-clinical safety and efficacy testing of AUM001 required to commence its Phase II clinical trial in Australia.

Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

READ

 

Recent Posts
by Sam Beattie on 2022-12-02 at 7:10pm

Terms Tracker for the Week Ending December 2nd, 2022 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. As we slide into December, and the holiday season, we recognized two new S-1 registration statements and zero IPOs. The two new S-1s consisted of...

by Marlena Haddad on 2022-12-02 at 5:38pm

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC Liquidations: NightDragon, VectoIQ II, and Fortistar Sustainable Solutions Corp. Night Dragon Acquisition Corp. Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination NightDragon Acquisition Corp. (NASDAQ: NDAC) anticipates that the last trading day...

by Marlena Haddad on 2022-12-02 at 4:38pm

Lakeshore Acquisition I Corp. (NASDAQ:LAAA) disclosed this afternoon that its shareholders have approved its business combination with medical device company ProSomnus during a special meeting held earlier today. Approximately 92.4% of the votes cast at the meeting on the business combination proposal, representing approximately 80.5% of Lakeshore’s outstanding shares, voted to approve the deal. The SPAC disclosed...

by Marlena Haddad on 2022-12-02 at 11:38am

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News: Embark director Elaine Chao and others sued over SPAC merger, Alvotech switches CEO and takes COO from Teva, and Uber Freight and Aurora expand pilot  Embark Director Elaine Chao, Others Sued Over SPAC...

by Nicholas Alan Clayton on 2022-12-02 at 7:51am

SPACInsider contributors Anthony Sozzi and Sam Beattie this week compiled their three favorite potential SPAC targets among potential targets in the security industry. We look at why they are compelling and why each could be a fit for a blank-check merger. Security is on the market’s mind and is expected to grow at a CAGR...

Privacy Policy|Terms Of Use
Copyright © 2022 SPACInsider, Inc. All Rights Reserved